SPRB · Insider Trading
Spruce Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by SPRB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-29 | Adrian W Quartel | Chief Medical Officer | A | +13,000 deriv. | — |
| 2026-07-09 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | A | +266 | +$1.21K |
| 2026-05-26 | Michael G Grey | Executive Chairman | A | +1,700 deriv. | — |
| 2026-05-26 | Percival Barretto-Ko | Director | A | +1,700 deriv. | — |
| 2026-05-26 | Camilla V Simpson | Director | A | +1,700 deriv. | — |
| 2026-05-26 | Keli Walbert | Director | A | +1,700 deriv. | — |
| 2026-05-26 | Daniel K Spiegelman | Director | A | +1,700 deriv. | — |
| 2026-03-09 | Corwin Dale Hooks | Chief Commercial Officer | A | +11,000 deriv. | — |
| 2026-01-21 | Douglas Kirk Ways | Interim Chief Medical Officer | M | +1,250 | — |
| 2026-01-05 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | A | +4,690 | +$21.25K |
| 2025-12-17 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | +647 | −$29.20K |
| 2025-12-17 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | +1,316 | −$109.71K |
| 2025-12-15 | Keli Walbert | Director | A | +3,400 deriv. | — |
| 2025-12-15 | Percival Barretto-Ko | Director | MIXED | — | — |
| 2025-12-15 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-12-15 | Michael G Grey | Executive Chairman | MIXED | — | — |
| 2025-12-15 | Daniel K Spiegelman | Director | MIXED | — | — |
| 2025-12-15 | Camilla V Simpson | Director | MIXED | — | — |
| 2025-12-15 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | — | — |
| 2025-12-12 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | +3,524 | −$230.64K |
| 2025-12-12 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | +1,550 | −$75.88K |
| 2025-10-22 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | +3,245 | −$228.02K |
| 2025-10-22 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | +1,392 | −$97.93K |
| 2025-10-15 | Gregory Martinez | 10%+ Owner | MIXED | −1 | −$335 |
| 2025-10-08 | Parkman Healthcare Partners LLC | 10%+ Owner | MIXED | −1 | −$335 |
| 2025-07-24 | Bali Muralidhar | Director | A | +30,000 deriv. | — |
| 2025-07-24 | Camilla V Simpson | Director | A | +30,000 deriv. | — |
| 2025-07-24 | Tiba Aynechi | Director | A | +30,000 deriv. | — |
| 2025-07-24 | Kirk Ways | Interim Chief Medical Officer | A | +30,000 deriv. | — |
| 2025-07-24 | Percival Barretto-Ko | Director | A | +30,000 deriv. | — |
| 2025-07-24 | Daniel K Spiegelman | Director | A | +30,000 deriv. | — |
| 2025-07-24 | Michael G Grey | Executive Chairman | A | +30,000 deriv. | — |
| 2024-12-20 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | +359,870 | −$96.58K |
| 2024-12-20 | Ralph William Charlton III | CHIEF MEDICAL OFFICER | MIXED | +105,966 | −$28.48K |
| 2024-12-20 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | +147,774 | −$40.01K |
| 2024-05-24 | Daniel K Spiegelman | Director | A | +30,000 deriv. | — |
| 2024-05-24 | Camilla V Simpson | Director | A | +30,000 deriv. | — |
| 2024-05-24 | Michael G Grey | Executive Chairman | A | +30,000 deriv. | — |
| 2024-05-24 | Bali Muralidhar | Director | A | +30,000 deriv. | — |
| 2024-05-24 | Tiba Aynechi | Director | A | +30,000 deriv. | — |
| 2024-05-24 | Kirk Ways | Director | A | +30,000 deriv. | — |
| 2024-05-24 | Percival Barretto-Ko | Director | A | +30,000 deriv. | — |
| 2024-03-25 | Novo Holdings A/S | 10%+ Owner | Sell | −465,021 | −$350.95K |
| 2024-03-20 | Novo Holdings A/S | 10%+ Owner | Sell | −1,794,999 | −$1.36M |
| 2024-03-18 | Samir M. Gharib | PRESIDENT AND CFO | A | +154,000 deriv. | — |
| 2024-03-18 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | A | +358,800 deriv. | — |
| 2024-03-18 | Ralph William Charlton III | CHIEF MEDICAL OFFICER | A | +106,400 deriv. | — |
| 2024-03-18 | Novo Holdings A/S | 10%+ Owner | Sell | −1,912,316 | −$1.70M |
| 2024-01-03 | Ralph William Charlton III | Chief Medical Officer | A | +9,361 | +$9.15K |
| 2024-01-03 | Samir M. Gharib | President & CFO | A | +11,255 | +$11.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bali Muralidhar | Director | 23,900 | $964.25K |
| Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | 19,270 | $777.45K |
| Samir M. Gharib | PRESIDENT AND CFO | 8,263 | $333.37K |
| Ralph William Charlton III | CHIEF MEDICAL OFFICER | 2,151 | $86.78K |
| Douglas Kirk Ways | Interim Chief Medical Officer | 1,250 | $50.43K |
| Parkman Healthcare Partners LLC | 10%+ Owner | 1,050 | $42.36K |
| Gregory Martinez | 10%+ Owner | 1,050 | $42.36K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SPRB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.